NeoGenomics raised full-year 2026 revenue guidance after reporting strong Q1 results, citing momentum in its NGS testing business. The company said NGS testing products contributed about one third of its clinical revenue and volume during the quarter. In a separate diagnostics and life-science tools update, Qiagen lowered full-year 2026 guidance following softness tied to reduced demand for latent tuberculosis immigration testing using its Quantiferon assays and caution among life science research customers. Qiagen said it expects a larger decline in Quantiferon performance tied to immigration policy changes. Both updates show how demand drivers outside pure clinical adoption—policy-linked testing volume and broader R&D spending—continue to influence revenue visibility for diagnostics suppliers. For biotech investors and operators, the guidance changes provide a near-term read on laboratory utilization and instrument-and-reagent demand cycles.